Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En første-i-menneskelig undersøgelse for at lære, hvordan Safe Bay 3713372 er, og hvordan det fungerer i deltagere med MTAP-slettede faste tumorer

10. november 2026 opdateret af: Bayer

En første-i-human undersøgelse til evaluering af sikkerheden, tolerabiliteten og farmakokinetikken, farmakodynamik og foreløbig klinisk aktivitet af BAY 3713372, en ny 2. generation PRMT5-hæmmer, hos deltagere med MTAP-slettede faste tumorer.

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.

The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.

For this, the researchers will study and analyze:

  • the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.
  • the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.
  • the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.
  • the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.

Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.

The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.

Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.

Participants will visit the study site:

  • at least twice before the treatment starts
  • multiple times when they start taking the treatment
  • once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason

During the study, the doctors and their study team will:

  • check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram
  • check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan
  • take tumor samples

The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

450

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • Rekruttering
        • Chris O'Brien Lifehouse
      • Concord, New South Wales, Australien, 2139
        • Rekruttering
        • Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
      • Epping, New South Wales, Australien, 3076
        • Ikke rekrutterer endnu
        • Northern Hospital
      • Waratah, New South Wales, Australien, 2298
        • Rekruttering
        • Calvary Mater Hospital Newcastle - Oncology
    • Antwerp
      • Antwerp, Antwerp, Belgien, 2650
        • Rekruttering
        • Antwerp University Hospital | Oncology Department
    • East Flanders
      • Ghent, East Flanders, Belgien, 9000
        • Rekruttering
        • Ghent University Hospital | Drug Research Unit Department
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgien, 3000
        • Rekruttering
        • UZ Leuven Gasthuisberg - Pneumology Department
    • Liège
      • Liège, Liège, Belgien, 4000
        • Rekruttering
        • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
    • Capital Region / Region Hovedstaden
      • Copenhagen, Capital Region / Region Hovedstaden, Danmark, 2100
        • Rekruttering
        • Rigshospitalet Copenhagen University Hospital | Oncology Department
    • Region of Southern Denmark / Region Syddanmark
      • Odense, Region of Southern Denmark / Region Syddanmark, Danmark, 5000
        • Rekruttering
        • Odense University Hospital | Svendborg Sygehus - Oncology Department
    • Greater Manchester
      • Manchester, Greater Manchester, Det Forenede Kongerige, M20 4BX
        • Rekruttering
        • The Christie Hospital | Experimental Cancer Medicine Team
    • Surrey
      • Sutton, Surrey, Det Forenede Kongerige, SM2 5PT
        • Ikke rekrutterer endnu
        • The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Ikke rekrutterer endnu
        • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
    • California
      • Duarte, California, Forenede Stater, 91010
        • Ikke rekrutterer endnu
        • City of Hope - Duarte Cancer Center
      • Los Angeles, California, Forenede Stater, 90095
        • Ikke rekrutterer endnu
        • UCLA Health Bowyer Oncology Center
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
      • Stanford, California, Forenede Stater, 94305
        • Ikke rekrutterer endnu
        • Stanford University Medical Center - Neurology
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Ikke rekrutterer endnu
        • UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
    • Florida
      • Orlando, Florida, Forenede Stater, 32827
        • Rekruttering
        • Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Ikke rekrutterer endnu
        • Dana-Farber Cancer Institute - Oncology Department
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital - Neurology
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49546
        • Rekruttering
        • START | Midwest
    • New York
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center New York - Main Campus
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai - Oncology
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • SCRI Oncology Partners
    • Texas
      • Irving, Texas, Forenede Stater, 75039
        • Rekruttering
        • NEXT Dallas - Oncology Department
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • START | San Antonio
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Ikke rekrutterer endnu
        • Froedtert Hospital - Clinical Cancer Center
    • North Holland
      • Amsterdam, North Holland, Holland, 1066 CX
        • Rekruttering
        • Nederlands Kanker Instituut
    • Provincie Groningen
      • Groningen, Provincie Groningen, Holland, 9713 GZ
        • Ikke rekrutterer endnu
        • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
    • South Holland
      • Rotterdam, South Holland, Holland, 3015 CE
        • Rekruttering
        • Erasmus Medisch Centrum
    • Friuli Venezia Giulia
      • Aviano, Friuli Venezia Giulia, Italien, 33081
        • Rekruttering
        • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
    • Lazio
      • Rome, Lazio, Italien, 00128
        • Rekruttering
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
      • Rome, Lazio, Italien, 00144
        • Ikke rekrutterer endnu
        • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
    • Lombardy
      • Milan, Lombardy, Italien, 20133
        • Rekruttering
        • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
      • Rozzano, Lombardy, Italien, 20089
        • Rekruttering
        • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 466-8560
        • Ikke rekrutterer endnu
        • Nagoya University Hospital
    • Osaka
      • Sakai, Osaka, Japan, 590-0197
        • Rekruttering
        • Kindai University Hospital
    • Shizuoka
      • Sunto, Shizuoka, Japan, 411-8777
        • Rekruttering
        • Shizuoka Cancer Center
    • Tokyo
      • Chuo-ku, Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center Hospital
      • Koto-ku, Tokyo, Japan, 135-8550
        • Rekruttering
        • The Cancer Institute Hospital of JFCR
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100142
        • Rekruttering
        • Beijing Cancer Hospital - Oncology Department
      • Beijing, Beijing Municipality, Kina, 101149
        • Ikke rekrutterer endnu
        • Beijing chest hospital, Capital Medical University
    • Hubei
      • Wuhan, Hubei, Kina, 430075
        • Rekruttering
        • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Ikke rekrutterer endnu
        • Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310016
        • Ikke rekrutterer endnu
        • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
    • Singapore
      • Singapore, Singapore, Singapore, 119074
        • Rekruttering
        • National University Hospital Medical Centre
      • Singapore, Singapore, Singapore, 168583
        • Rekruttering
        • National Cancer Center Singapore - Oncology Department
      • Singapore, Singapore, Singapore, 217562
        • Rekruttering
        • Icon Cancer Centre
    • Barcelona
      • Barcelona, Barcelona, Spanien, 08023
        • Rekruttering
        • Hospital Hm Nou Delfos | Oncologia
      • Barcelona, Barcelona, Spanien, 08035
        • Rekruttering
        • Hospital Universitari Vall D Hebron | Oncologia
    • Chartered Community of Navarre
      • Pamplona, Chartered Community of Navarre, Spanien, 31008
        • Rekruttering
        • Clinica Universidad De Navarra | Pamplona | Oncologia
    • La Rioja
      • Logroño, La Rioja, Spanien, 26006
        • Rekruttering
        • Hospital San Pedro | Oncologia
    • Madrid
      • Madrid, Madrid, Spanien, 28040
        • Rekruttering
        • Hospital Universitario Fundacion Jimenez Diaz | Oncologia
      • Pozuelo de Alarcón, Madrid, Spanien, 28223
        • Rekruttering
        • NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
    • Málaga
      • Málaga, Málaga, Spanien, 29010
        • Rekruttering
        • Hospital Universitario Virgen De La Victoria | Oncologia
    • Valencia
      • Valencia, Valencia, Spanien, 46010
        • Ikke rekrutterer endnu
        • Hospital Clinico Universitario De Valencia | Oncologia
    • Stockholm County
      • Stockholm, Stockholm County, Sverige, 171 76
        • Rekruttering
        • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Sverige, 413 46
        • Ikke rekrutterer endnu
        • Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
    • Olomouc Region
      • Olomouc, Olomouc Region, Tjekkiet, 779 00
        • Rekruttering
        • Fakultní nemocnice Olomouc - Onkologická klinika
    • South Moravian
      • Brno, South Moravian, Tjekkiet, 602 00
        • Rekruttering
        • Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent.
  • At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
  • Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

  • Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.

  • A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.

  • Cardiac history comprising:

    • History of congestive heart failure Class >II according to the New York Heart Association Functional Classification.
    • Myocardial infarction less than 6 months before the start of study intervention.
    • Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.
  • Unstable angina within 4 weeks before start of study intervention.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose Escalation (Intervention Cohort 1)

For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned.

Daily oral administration

Eksperimentel: Backfill cohorts in Intervention Cohort 1 (Dose Escalation)

Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development.

Daily oral administration

Eksperimentel: Dose Expansion (Intervention Cohort 1)

Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors.

Daily oral administration

Eksperimentel: Dose Expansion (Intervention Cohort 2)

Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC).

Daily oral administration

Eksperimentel: Dose Expansion (Intervention Cohort 3)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

Daily oral administration

Eksperimentel: Dose Expansion (Intervention Cohort 4)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

Daily oral administration

Eksperimentel: Dose Expansion (Intervention Cohort 5)

Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).

Daily oral administration

Eksperimentel: Dose Expansion (Intervention Cohort 6)

Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC.

Daily oral administration

Eksperimentel: Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)

A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM).

Daily oral administration

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Dosis Escalation (Master and Intervention Cohort 1): Maksimal koncentration (CMAX) af det respektive doseringsinterval i Bay 3713372
Tidsramme: Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage)
Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage)
Dosisoptrapning (master- og interventionskohort 1): Område under kurven (AUC) for det respektive doseringsinterval i Bay 3713372
Tidsramme: Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage)
Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage)
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)
Tidsramme: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs
Tidsramme: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)
Tidsramme: Approximately 1.5 years

Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Approximately 1.5 years
Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs
Tidsramme: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Intervention Cohort 7: Number of participants with DLTs
Tidsramme: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

Number of participants with at least one DLT

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372
Tidsramme: From first dose through day of surgery (approximately 7 ± 2 days)

Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios

From first dose through day of surgery (approximately 7 ± 2 days)
Intervention Cohort 7: Tumor tissue SDMA levels
Tidsramme: From first dose through day of surgery (approximately 7 ± 2 days)

Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition

From first dose through day of surgery (approximately 7 ± 2 days)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Dosis Escalation (Master and Intervention Cohort 1): Tid til respons (TTR)
Tidsramme: Ca. 1,5 år
Ca. 1,5 år
Dosisudvidelse (master, interventionskohorter 1 - 6): Tid til respons (TTR)
Tidsramme: Ca. 1,5 år
Ca. 1,5 år
Dosisudvidelse (master, interventionskohorter 1 - 4 og 6): Maksimal koncentration (Cmax) af det respektive doseringsinterval i Bay 3713372
Tidsramme: Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage, bortset fra interventionskohort 6, som har en cykluslængde på 28 dage)
Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage, bortset fra interventionskohort 6, som har en cykluslængde på 28 dage)
Dosisudvidelse (master, interventionskohorter 1 - 4 og 6): Område under kurven (AUC) for det respektive doseringsinterval i Bay 3713372
Tidsramme: Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage, bortset fra interventionskohort 6, som har en cykluslængde på 28 dage)
Fra den første dosis af undersøgelsesintervention op til cyklus 2 dag 1 (hver cyklus er 21 dage, bortset fra interventionskohort 6, som har en cykluslængde på 28 dage)
Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)
Tidsramme: Approximately 3 years
Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases
Tidsramme: Approximately 1.5 years
Approximately 1.5 years
Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)
Tidsramme: Approximately 1.5 years

Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Approximately 1.5 years
Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)
Tidsramme: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)
Tidsramme: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Tidsramme: From the first administration of study intervention up to 30 days after the last dose of study intervention

TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

From the first administration of study intervention up to 30 days after the last dose of study intervention
Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)
Tidsramme: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)
Tidsramme: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)
Tidsramme: Approximately 3 years

Determined by the investigator according to RECIST v1.1

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases
Tidsramme: Approximately 1.5 years

CNS-ORR: CNS objective response rate

Approximately 1.5 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases
Tidsramme: Approximately 3 years

CNS-DOR: Duration of CNS response

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases
Tidsramme: Approximately 3 years

CNS-PFS: Survival without CNS progression

Approximately 3 years
Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases
Tidsramme: Approximately 1.5 years

CNS-TTR: Time to CNS response

Approximately 1.5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. marts 2025

Primær færdiggørelse (Anslået)

18. juni 2029

Studieafslutning (Anslået)

18. juni 2029

Datoer for studieregistrering

Først indsendt

31. marts 2025

Først indsendt, der opfyldte QC-kriterier

31. marts 2025

Først opslået (Faktiske)

6. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner